Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

MDM2 inhibition: an important step forward in cancer therapy

(2020) Marina Konopleva et al.   LEUKEMIA

Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway

(2020) Yingying Cui et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells

(2019) Umamaheswari Natarajan et al.   Medicina-Lithuania

Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells

(2018) Umamaheswari Natarajan et al.   Cells

Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1

(2017) A Cosson et al.   LEUKEMIA

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

(2017) Maryam Zanjirband et al.   Oncotarget

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia

(2016) Thomas B. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

(2016) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver

(2016) QIAO-LING XIE et al.   Experimental and Therapeutic Medicine

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma

(2016) Manoj Garg et al.   Oncotarget

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

(2015) Z. A. Hing et al.   BLOOD

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program

(2015) Edward F. Attiyeh et al.   PEDIATRIC BLOOD & CANCER

Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein

(2015) Jo Ishizawa et al.   PHARMACOLOGY & THERAPEUTICS

KPT-330 has antitumour activity against non-small cell lung cancer

(2014) H Sun et al.   BRITISH JOURNAL OF CANCER

Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy

(2014) Min Lu et al.   FEBS LETTERS

Nucleo-cytoplasmic transport as a therapeutic target of cancer

(2014) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

Ovarian cancer

(2014) Gordon C Jayson et al.   LANCET

Antitumor Effects of a Novel Chromosome Region Maintenance 1 (CRM1) Inhibitor on Non-Small Cell Lung Cancer Cells In Vitro and in Mouse Tumor Xenografts

(2014) Shuai Wang et al.   PLoS One

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

(2013) Julia Etchin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas

(2013) Fang Zhou et al.   MEDICAL ONCOLOGY

p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1

(2013) Aleixo Santiago et al.   MOLECULAR BIOLOGY OF THE CELL

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

(2013) Qingxiang Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome

(2012) Kirsty M. Brodie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

NESdb: a database of NES-containing CRM1 cargoes

(2012) Darui Xu et al.   MOLECULAR BIOLOGY OF THE CELL

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

(2011) K. Sakakibara et al.   BLOOD

Protein and its function based on a subcellular localization

(2011) Jana Ćmielová et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

(2009) J. G. Turner et al.   CANCER RESEARCH

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

(2009) S. C. Mutka et al.   CANCER RESEARCH

Dysregulation of apoptosis in hepatocellular carcinoma cells

(2009) Isabel Fabregat   WORLD JOURNAL OF GASTROENTEROLOGY

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation

(2008) Pauline J. van der Watt et al.   INTERNATIONAL JOURNAL OF CANCER